Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
CRISPR Therapeutics
CRSP
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$48.86
0.68
1.41%
Pre-Market: 8:26 AM EDT
15 minutes delayed
Get Report
Comment
CRISPR Therapeutics (CRSP) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for CRISPR Therapeutics (NASDAQ:CRSP) Stock
CRISPR Therapeutics Stock (NASDAQ: CRSP)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, August 12, 2024
Truist Securities Maintains Buy on CRISPR The...
Benzinga Newsdesk
Thursday, August 08, 2024
Cantor Fitzgerald Reiterates Neutral on CRISP...
Benzinga Newsdesk
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
Avi Kapoor
Tuesday, August 06, 2024
Barclays Maintains Equal-Weight on CRISPR The...
Benzinga Newsdesk
RBC Capital Maintains Sector Perform on CRISP...
Benzinga Newsdesk
Stifel Maintains Hold on CRISPR Therapeutics,...
Benzinga Newsdesk
Chardan Capital Maintains Buy on CRISPR Thera...
Benzinga Newsdesk
Needham Maintains Buy on CRISPR Therapeutics,...
Benzinga Newsdesk
Monday, August 05, 2024
CRISPR Therapeutics Q2 2024 Adj EPS $(1.49) B...
Benzinga Newsdesk
Thursday, July 11, 2024
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
Benzinga Neuro
Friday, June 28, 2024
Guggenheim Assumes CRISPR Therapeutics at Neu...
Benzinga Newsdesk
Thursday, June 27, 2024
Needham Reiterates Buy on CRISPR Therapeutics...
Benzinga Newsdesk
Tuesday, June 25, 2024
Intellia Therapeutics Presents Data On Redosi...
Benzinga Newsdesk
Monday, June 17, 2024
Piper Sandler Reiterates Overweight on CRISPR...
Benzinga Newsdesk
Needham Reiterates Buy on CRISPR Therapeutics...
Benzinga Newsdesk
Thursday, May 23, 2024
Citigroup Maintains Buy on CRISPR Therapeutic...
Benzinga Newsdesk
CRISPR Therapeutics' Julianne Bruno, M.B.A., ...
Benzinga Newsdesk
Friday, May 10, 2024
Oppenheimer Maintains Outperform on CRISPR Th...
Benzinga Newsdesk
Thursday, May 09, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Wells Fargo Maintains Equal-Weight on CRISPR ...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Neutral on CRISP...
Benzinga Newsdesk
Barclays Maintains Equal-Weight on CRISPR The...
Benzinga Newsdesk
Needham Maintains Buy on CRISPR Therapeutics,...
Benzinga Newsdesk
Baird Maintains Neutral on CRISPR Therapeutic...
Benzinga Newsdesk
Wednesday, May 08, 2024
CRISPR Therapeutics Q1 EPS $(1.43) Misses $(1...
Benzinga Newsdesk
Thursday, April 18, 2024
Citigroup Maintains Buy on CRISPR Therapeutic...
Benzinga Newsdesk
Wednesday, April 17, 2024
CRISPR Therapeutics's Options Frenzy: What You Need to Know
Benzinga Insights
Thursday, April 11, 2024
Needham Reiterates Buy on CRISPR Therapeutics...
Benzinga Newsdesk
Thursday, March 21, 2024
Smart Money Is Betting Big In CRSP Options
Benzinga Insights
Tuesday, March 19, 2024
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
Benzinga Insights
Wednesday, March 13, 2024
Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz
Benzinga Neuro
Wednesday, March 06, 2024
Mizuho Maintains Buy on CRISPR Therapeutics, ...
Benzinga Newsdesk
Monday, March 04, 2024
Smart Money Is Betting Big In CRSP Options
Benzinga Insights
Monday, February 26, 2024
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
Vandana Singh
Morgan Stanley Maintains Underweight on CRISP...
Benzinga Newsdesk
Friday, February 23, 2024
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
Benzinga Insights
Thursday, February 22, 2024
Smart Money Is Betting Big In CRSP Options
Benzinga Insights
RBC Capital Maintains Sector Perform on CRISP...
Benzinga Newsdesk
CRISPR Therapeutics shares are trading higher...
Benzinga Newsdesk
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
Chardan Capital Maintains Buy on CRISPR Thera...
Benzinga Newsdesk
Wednesday, February 21, 2024
Needham Maintains Buy on CRISPR Therapeutics,...
Benzinga Newsdesk
CRISPR Therapeutics Q4 EPS $1.10 Vs $(1.41) Y...
Benzinga Newsdesk
Thursday, February 15, 2024
What's Going On With Crispr Therapeutics Stock?
Erica Kollmann
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
Avi Kapoor
Wolfe Research Initiates Coverage On CRISPR T...
Benzinga Newsdesk
Wednesday, February 14, 2024
Check Out What Whales Are Doing With CRSP
Benzinga Insights
Tuesday, February 13, 2024
CRISPR Therapeutics Announces $280M Registere...
Benzinga Newsdesk
European Commission Approves First CRISPR/Cas...
Benzinga Newsdesk
Friday, February 09, 2024
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Benzinga Insights
Show More
